“Empagliflozin May Prevent Lung Damage and Acute Respiratory Illness during Influenza Infection in Type II Diabetes Patients”

https://pubmed.ncbi.nlm.nih.gov/38112660

Empagliflozin, a medication for type II diabetes, may help prevent lung damage and acute respiratory illness during influenza infection by suppressing the inflammatory immune response, despite increasing viral burden.